Clinical Trial Update: Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated how rifabutin alters the pharmacokinetics of the cystic fibrosis TRIKAFTA combo (elexacaftor/tezacaftor/ivacaftor); the study has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Mycobutin (rifabutin)
• TRIKAFTA (ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR)

Snippet

Sponsor: University of Southern California | Conditions: Drug Drug Interaction | Phase 4 | Status: COMPLETED